Biolojic Design Joins Johnson & Johnson Innovation - JLABS Biolojic Design expands U.S. presences by becoming a resident company at Johnson & Johnson JLABS DC

Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany Biolojic Design Enters into Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany in oncology and immunology

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology

Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease TEL AVIV, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Biolojic Design (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced that it has entered into...